Opportunity ID: 356384

General Information

Document Type: Grants Notice
Funding Opportunity Number: EDS-EDS-24-001
Funding Opportunity Title: Emergency Department Substance Use Surveillance System
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 1
Assistance Listings: 95.007 — Research and Data Analysis
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 10, 2024
Last Updated Date: Sep 10, 2024
Original Closing Date for Applications: Sep 17, 2024 No Explanation
Current Closing Date for Applications: Sep 17, 2024 No Explanation
Archive Date: Oct 17, 2024
Estimated Total Program Funding:
Award Ceiling: $150,000
Award Floor: $0

Eligibility

Eligible Applicants: Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Additional Information on Eligibility:

Additional Information

Agency Name: Office of National Drug Control Policy
Description: This project seeks to further refine and geographically expand a methodology for obtaining drug early warning indicators through broader testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations – including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. A similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including xylazine, fentanyl, methamphetamine, and other new psychoactive substances (NPS); to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. Bypassing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. Hospital and de-identified nationally representative patient electronic health records (EHRs) should be collected and analyzed to put re-tested urine positivity results into a larger regional and national context of drug exposure and consequences. ONDCP is seeking to apply this testing methodology and insight from supplemental EHR investigations to emergency department and other hospital-system populations in locations throughout the United States to reinforce best practice guidelines, testing standardization, and build local and national surveillance capacity.
Link to Additional Information: Emergency Department Substance Use Surveillance System
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Grants.gov Contact Center
Phone Number: 1-800-518-4726

Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays.
Email:-

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: Grants.gov Contact Center
Phone Number: 1-800-518-4726

Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays.

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
PKG00287884 Sep 10, 2024 Sep 17, 2024 View

Package 1

Mandatory forms

356384 SF424_4_0-4.0.pdf

356384 SF424B-1.1.pdf

356384 SF424A-1.0.pdf

356384 BudgetNarrativeAttachments_1_2-1.2.pdf

356384 SFLLL_2_0-2.0.pdf

Optional forms

356384 SF424D-1.1.pdf

356384 AttachmentForm_1_2-1.2.pdf

356384 SF424C_2_0-2.0.pdf

2025-07-13T08:17:51-05:00

Share This Post, Choose Your Platform!

About the Author: